PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Epstein-Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions.

Abstract The Epstein-Barr virus (EBV) plays a key role in the development of undifferentiated nasopharyngeal carcinoma (uNPC). In uNPC endemic regions EBV-specific antibodies and plasma EBV DNA load are used as markers for the early detection of uNPC and monitoring of the disease. In non-endemic regions, such studies were practically not conducted. The aim of this study was to compare the clinical significance of EBV serological markers and plasma EBV DNA levels for uNPC patients in a non-endemic region, Russia. The results obtained indicate that both viral capsid antigen/immunoglobulin A (VCA/IgA) antibodies and plasma EBV DNA copies can effectively be used for nasopharyngeal carcinoma (NPC) diagnosis. Besides, plasma EBV DNA load was found to be a more sensitive marker of uNPC than VCA/IgA antibody titres, as it reflected the effect of the therapy in stages of remission and relapse of the disease more precisely. Our study, for the first time, demonstrates that the simultaneous use of plasma EBV DNA loads and VCA/IgA antibody levels are indispensable markers for uNPC in non-endemic regions: a serological marker can be more effectively used for NPC screening, but EBV DNA copies are better for monitoring the disease. However, both markers turned out to be practically unsuitable for assessing the clinical status of patients. Serological markers did not correlate with any signs of the tumour process estimated by tumour, node and metastasis (TNM) classification and the plasma EBV DNA loads correlated only with the size of the pathologically altered lymph nodes (N). Additional study is required to confirm these findings.
PMID
Related Publications

Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma.

Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.

Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.

Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study.

Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.

Authors

Mayor MeshTerms
Keywords
Journal Title the journal of general virology
Publication Year Start




PMID- 28786806
OWN - NLM
STAT- MEDLINE
DA  - 20170808
DCOM- 20170906
LR  - 20170906
IS  - 1465-2099 (Electronic)
IS  - 0022-1317 (Linking)
VI  - 98
IP  - 8
DP  - 2017 Aug
TI  - Epstein-Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic
      regions.
PG  - 2118-2127
LID - 10.1099/jgv.0.000889 [doi]
AB  - The Epstein-Barr virus (EBV) plays a key role in the development of
      undifferentiated nasopharyngeal carcinoma (uNPC). In uNPC endemic regions
      EBV-specific antibodies and plasma EBV DNA load are used as markers for the early
      detection of uNPC and monitoring of the disease. In non-endemic regions, such
      studies were practically not conducted. The aim of this study was to compare the 
      clinical significance of EBV serological markers and plasma EBV DNA levels for
      uNPC patients in a non-endemic region, Russia. The results obtained indicate that
      both viral capsid antigen/immunoglobulin A (VCA/IgA) antibodies and plasma EBV
      DNA copies can effectively be used for nasopharyngeal carcinoma (NPC) diagnosis. 
      Besides, plasma EBV DNA load was found to be a more sensitive marker of uNPC than
      VCA/IgA antibody titres, as it reflected the effect of the therapy in stages of
      remission and relapse of the disease more precisely. Our study, for the first
      time, demonstrates that the simultaneous use of plasma EBV DNA loads and VCA/IgA 
      antibody levels are indispensable markers for uNPC in non-endemic regions: a
      serological marker can be more effectively used for NPC screening, but EBV DNA
      copies are better for monitoring the disease. However, both markers turned out to
      be practically unsuitable for assessing the clinical status of patients.
      Serological markers did not correlate with any signs of the tumour process
      estimated by tumour, node and metastasis (TNM) classification and the plasma EBV 
      DNA loads correlated only with the size of the pathologically altered lymph nodes
      (N). Additional study is required to confirm these findings.
FAU - Gurtsevitch, V E
AU  - Gurtsevitch VE
AD  - N. N. Blokhin Russian Cancer Research Center, Kashirskoe shosse 24, 115478
      Moscow, Russia.
FAU - Senyuta, N B
AU  - Senyuta NB
AD  - N. N. Blokhin Russian Cancer Research Center, Kashirskoe shosse 24, 115478
      Moscow, Russia.
FAU - Ignatova, A V
AU  - Ignatova AV
AD  - N. N. Blokhin Russian Cancer Research Center, Kashirskoe shosse 24, 115478
      Moscow, Russia.
FAU - Lomaya, M V
AU  - Lomaya MV
AD  - N. N. Blokhin Russian Cancer Research Center, Kashirskoe shosse 24, 115478
      Moscow, Russia.
FAU - Kondratova, V N
AU  - Kondratova VN
AD  - N. N. Blokhin Russian Cancer Research Center, Kashirskoe shosse 24, 115478
      Moscow, Russia.
FAU - Pavlovskaya, A I
AU  - Pavlovskaya AI
AD  - N. N. Blokhin Russian Cancer Research Center, Kashirskoe shosse 24, 115478
      Moscow, Russia.
FAU - Dushenkina, T E
AU  - Dushenkina TE
AD  - N. N. Blokhin Russian Cancer Research Center, Kashirskoe shosse 24, 115478
      Moscow, Russia.
FAU - Maximovich, D M
AU  - Maximovich DM
AD  - N. N. Blokhin Russian Cancer Research Center, Kashirskoe shosse 24, 115478
      Moscow, Russia.
FAU - Smirnova, K V
AU  - Smirnova KV
AD  - N. N. Blokhin Russian Cancer Research Center, Kashirskoe shosse 24, 115478
      Moscow, Russia.
FAU - Mudunov, A M
AU  - Mudunov AM
AD  - N. N. Blokhin Russian Cancer Research Center, Kashirskoe shosse 24, 115478
      Moscow, Russia.
FAU - Lichtenstein, A V
AU  - Lichtenstein AV
AD  - N. N. Blokhin Russian Cancer Research Center, Kashirskoe shosse 24, 115478
      Moscow, Russia.
LA  - eng
PT  - Journal Article
DEP - 20170808
PL  - England
TA  - J Gen Virol
JT  - The Journal of general virology
JID - 0077340
RN  - 0 (Antibodies, Viral)
RN  - 0 (Capsid Proteins)
RN  - 0 (DNA, Viral)
RN  - Nasopharyngeal carcinoma
SB  - IM
MH  - Adult
MH  - Antibodies, Viral/blood
MH  - Capsid Proteins/genetics/metabolism
MH  - Carcinoma/blood/*virology
MH  - DNA, Viral/genetics/metabolism
MH  - Epstein-Barr Virus Infections/blood/*virology
MH  - Female
MH  - Herpesvirus 4, Human/classification/genetics/immunology/*isolation & purification
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasopharyngeal Neoplasms/blood/*virology
MH  - Russia
EDAT- 2017/08/09 06:00
MHDA- 2017/09/07 06:00
CRDT- 2017/08/09 06:00
AID - 10.1099/jgv.0.000889 [doi]
PST - ppublish
SO  - J Gen Virol. 2017 Aug;98(8):2118-2127. doi: 10.1099/jgv.0.000889. Epub 2017 Aug
      8.